Linked regulatory filings and source documents are published in Chinese. English titles are provided for navigation; the original documents govern.
Investor Relations
投资者关系
Corporate Governance
Company Articles of Association and records of previous revisions. Click on the file name to download the PDF, with the latest version prioritized.
- September 2025 Bio-Thera Solutions, Ltd. Articles of Association (revised in September 2025) Latest
- August 2025 Bio-Thera Solutions, Ltd. Articles of Association (revised in August 2025) Revised
- April 2025 Bio-Thera Solutions, Ltd. Articles of Association (revised in April 2025) Revised
- September 2021 Bio-Thera Solutions, Ltd. Articles of Association (Revised September 2021) PDF
- August 2021 Articles of Association of Bio-Thera Solutions, Ltd. (revised in August 2021) PDF
- July 2020 Bio-Thera Solutions, Ltd. Articles of Association (draft revised in July 2020) Draft
- April 2020 Bio-Thera Solutions, Ltd. Articles of Association (revised in April 2020) Not Available
Financial Reports
Annual, semi-annual and quarterly reports. Click on a year to expand the file list.
2026
2025
2024
2023
2022
Announcements
Temporary announcements and voluntary disclosures covering the full official archive.
-
2026.8
-
2026.8
-
2026.8
-
2026.8
-
2026.8
Voluntary disclosure announcement of Bio-Thera’s 2026 semi-annual performance forecast
-
2026.8
-
2026.8
Bio-Thera’s announcement on EUGMP inspection status of Yonghe factory
-
2026.8
-
2026.6
-
2026.6
Bio-Thera 2025 Annual Shareholders Meeting Resolution Announcement
-
2026.6
-
2026.6
-
2026.6
Announcement of Resolutions of Bio-Thera’s Second Extraordinary Shareholders’ Meeting in 2026
-
2026.4
-
2026.4
-
2026.4
-
2026.4
Bio-Thera’s announcement on applying for a credit line from a financial institution
-
2026.4
Bio-Thera’s Announcement on Re-appointment of Accounting Firm
-
2026.4
-
2026.4
-
2026.4
-
2026.4
Bio-Thera’s Notice on Convening the 2025 Annual Shareholders Meeting
-
2026.4
Announcement of the Resolutions of the Eighth Meeting of the Third Board of Directors of Bio-Thera
-
2026.4
-
2026.4
-
2026.4
Bio-Thera’s Notice on Convening the Second Extraordinary Shareholders Meeting in 2026
-
2026.4
-
2026.3
-
2026.3
-
2026.3
-
2026.2
-
2026.2
Bio-Thera Announces Acceptance of the Marketing Authorization Application for BAT4406F Injection
-
2026.2
-
2026.2
Announcement of Resolutions of Bio-Thera’s First Extraordinary Shareholders Meeting in 2026
-
2026.2
-
2026.2
Bio-Thera’s announcement on changing the sponsor representative
-
2026.1
-
2026.1
Bio-Thera’s announcement on the return of funds raised to temporarily supplement working capital
-
2026.1
Bio-Thera’s Notice on Convening the First Extraordinary Shareholders Meeting in 2026
-
2026.1
-
2026.1
-
2026.1
-
2026.1
-
2026.1
Bio-Thera’s announcement on changing the project quality control reviewer
-
2026.1
Bio-Thera’s announcement on the company’s expected daily related transactions in 2026
-
2025.12
-
2025.12
-
2025.12
-
2025.12
Bio-Thera’s announcement on convening the 2025 third-quarter results briefing
-
2025.12
-
2025.12
Bio-Thera’s announcement on the departure of a key technical personnel
Investor contact information
For investor inquiries, please contact the Board of Directors office as follows.
- Board of Directors Office
- (020) 3220 3528
- Investor relations email
- IR@bio-thera.com
- Fax
- (020) 3220 3528
- Postal code
- 510005
- Contact address
- No. 18, Luoxuan 2nd Road, International Bio Island, Guangzhou City, Guangdong Province
Investor Protection
Identify risks and protect legitimate rights and interests. The following are key points for investor education.
- Study, publicize and implement Xi Jinping’s Thought on the Rule of Law to promote the Constitution’s popular support
- 12.4 National Constitution Day
- Beware of illegal fund-raising in the name of financial management or investment
- Stay away from illegal transfer of NEEQ stocks
- Check product registration status before purchasing private equity funds
- Basic attributes of private equity funds
- Anyone who allocates funds for stock trading and asks for transfer is a scam.
- High returns come with high risks
- Stock Recommendations via Livestreams Violate Regulations
- It is illegal to recommend stocks without securities consulting qualifications
- Boycott illegal securities and futures fund activities
- Beware of Impersonated Securities Firms: Verify Credentials to Avoid Fraud
- Pay attention to identify the authenticity of investment information
- To avoid being deceived in investment and financial management, checking your qualifications is the key